• Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
  • Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
  • Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
  • Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at $0.29 per share

Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).

In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year

Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.

Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at $0.29 per share. 


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.